Back to search results

Observational Study of Heart and Liver Stiffness in Heart Failure

This observational study aims to understand how a new ultrasound device, the eMyosound LYRA, can measure stiffness in the heart and liver. Researchers want to see if these measurements, called shear wave velocity (SWV), can help in patients with heart failure where the heart pumps normally (HFpEF - Heart Failure with Preserved Ejection Fraction), or with slightly reduced pumping (HFmrEF), and in those with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which causes the heart to thicken. You could be eligible if you are 60 years or older. The study will compare SWV measurements in these patient groups to a control group without heart problems. The main goal is to see if SWV can be reliably measured in these populations. The study status is unclear, and it plans to enroll 150 participants.

Study design
This is an observational study with three groups of participants. It is designed to understand how a new ultrasound device works in different patient populations.
What's involved
You will have one study visit lasting about 2.5 hours. This visit will include a physical exam, blood tests, and an echocardiogram.
Compensation
Not stated in the trial record.
Follow-up
No long-term follow-up visits are required after your single study visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215715

US Benchmarking Clinical Study

Recruiting
Not specifiedAges 60+Observational
eMyosound SAS
~150 participants
Updated 2025-10-20 on ClinicalTrials.gov

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary outcome measures are the shear wave velocity (SWV) measurements extracted from the eMyosound LYRA device acquisitions.
Measured over single study visit of a duration of approximatively 2.5 hours

Conditions

HFpEF - Heart Failure With Preserved Ejection Fraction
HFmrEF
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Left Ventricular Hypertrophy
Cardiac Amyloidosis

Explore related trials

Heart FailureLeft Ventricular HypertrophyTransthyretin related familial amyloid cardiomyopathy

Where it's being run

3 sites across 1 states
Massachusetts3

Study leadership

  • Thierry Sarda · STUDY_DIRECTOR · eMyosound SAS

Who to contact

Director Clinical Operations
[email protected]
+33781549847
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The primary outcome measures are the shear wave velocity (SWV) measurements extracted from the eMyosound LYRA device acquisitions.single study visit of a duration of approximatively 2.5 hours

    These measurements include: Myocardial Acoustic Radiation Force (ARF)-SWV, defined as the velocity projected along the muscle fibers during diastasis. Myocardial Natural (N)-SWV, measured during both mitral valve closure (MVC) and aortic valve closure (AVC). Hepatic ARF-SWV, measured in two distinct regions of the right liver lobe.